IVVD Stock — Invivyd Inc.: Cash, EV, Pipeline

Share price

$0.76

Market cap

$222.6M

Cash

$160.1M

Enterprise value

$62.5M

Balance sheet

Cash	$160.1M
Debt	$0.0M
Net cash	$160.1M
Enterprise value	$62.5M
Basic shares	294.8M shares
Fully diluted shares	332.6M shares
Fully diluted market cap	$252.8M
Cash per share	$0.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IVVD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	VYD2311-SD	Phase 3	COVID-19	Q3 2026
Now - Oct 24, 2026	VYD2311	Phase 3	COVID-19	Q3 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VYD2311

Phase 3 · Active Modality: monoclonal antibody

Target SARS-CoV-2

Partnerships Adimab: platform transfer agreement; WuXi Biologics: cell line license

Indications

COVID-19 prevention (Phase 3)

Catalysts

— Later Q3 2026
— Later Q3 2026

Status note REVOLUTION program includes three trials: DECLARATION (Phase 3 prevention, enrollment completed June 2026, supports potential BLA), LIBERTY (Phase 3 vs mRNA vaccine, fully dosed), and DRUMMER (pediatric, to be actioned only if DECLARATION succeeds). Fast Track designation for COVID-19 prevention.

PEMGARDA

Approved · Active Modality: monoclonal antibody (half-life extended)

Target SARS-CoV-2

Indications

COVID-19 pre-exposure prophylaxis (immunocompromised) (Stage not disclosed)

Catalysts

— June 29, 2027

Status note Authorized under EUA since March 22, 2024. Company in dialogue with FDA on next steps following EUA termination.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VYD2311-SD
Lead indication	COVID-19
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07298434	Phase 3	Active, not recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026
NCT07655180	Phase 3	Recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026
NCT06523153	Phase 1	Active, not recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Invivyd, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	3,807,427	-15,000	0.16%	2026-08-14
Ikarian Capital	2,656,570	no change	0.38%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IVVD — Invivyd Inc.